MENU

MREO Stock Mereo BioPharma Group (MREO, $1.63) RSI Indicator left the oversold zone on August 05, 2025

A.I.dvisor
at Tickeron.com
Loading...
MREO - Mereo BioPharma Group plc
RSI signal
Bullish Trend
Odds of UP Trend
Tickeron
RSI signal
Price: $1.63
Daily change: -$0.03 (-1.81%)
Daily volume: 1.1M
Capitalization: $259.2M
Industry: Biotechnology
This is a signal that MREO's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options. A.I.dvisor looked back and found 29 similar cases where MREO's RSI Indicator left the oversold zone, and in of them led to a successful outcome. Odds of Success:

MREO's RSI Oscillator is remaining in oversold zone for 1 day

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for MREO just turned positive on July 31, 2025. Looking at past instances where MREO's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MREO advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .

MREO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 128 cases where MREO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 31, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on MREO as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

MREO moved below its 50-day moving average on July 10, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for MREO crossed bearishly below the 50-day moving average on July 14, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MREO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.207) is normal, around the industry mean (18.047). P/E Ratio (0.000) is within average values for comparable stocks, (58.309). MREO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.504). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (344.828) is also within normal values, averaging (276.800).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MREO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MREO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. MREO showed earnings on May 13, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a company, which engages in therapeutics that aim to improve outcomes for patients with osteogenesis imperfecta, alpha-1 antitrypsin deficiency, hypogonadotropic hypogonadism in obese men, and acute exacerbations of chronic obstructive pulmonary disease

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
One Cavendish Place
Phone
+44 3330237300
Employees
33
Web
https://www.mereobiopharma.com